Population
In vitro biochemical model studying CPI-17 and Rho-kinase
Design
Preclinical
Authors
Loading...
Hypothesis-generating for Ca²⁺ sensitization in vascular smooth muscle; requires human validation before clinical consideration.
CPI-17 acts as a downstream effector of Rho-kinase, mediating Ca2+ sensitization of smooth muscle contraction through myosin phosphatase inhibition.
Koyama et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: